DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Erlotinib
Drug: Hydroxychloroquine

First Posted Date: 2009-09-15

Last Posted Date: 2020-07-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 76

Registration Number: NCT00977470

Locations: 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States

and more 1 locations

Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma

Not Applicable

Completed

Conditions: Liver Cancer

Interventions: Radiation: Proton Beam Irradiation

First Posted Date: 2009-09-15

Last Posted Date: 2018-08-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 83

Registration Number: NCT00976898

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Pennsylvania, Roberts Proton Facility, Philadelphia, Pennsylvania, United States

and more 1 locations

Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2009-09-15

Last Posted Date: 2017-04-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 45

Registration Number: NCT00977275

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Prednisone
Drug: Vincristine
Drug: Doxorubicin
Drug: PEG-asparaginase
Drug: Cytarabine
Drug: Methotrexate
Drug: Imatinib
Drug: Clofarabine
Drug: 6 Mercaptopurine

First Posted Date: 2009-09-09

Last Posted Date: 2017-03-30

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT00973752

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Novel Unidirectional Face Mask During NPPV in COPD Patients

Not Applicable

Withdrawn

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Device: A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)

First Posted Date: 2009-09-09

Last Posted Date: 2017-01-16

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00972868

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Using Video Images to Improve Advance Care Planning in Patients With Cancer

Not Applicable

Completed

Conditions: Advanced Cancer

Interventions: Behavioral: video

First Posted Date: 2009-09-02

Last Posted Date: 2012-05-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 80

Registration Number: NCT00970125

Locations: 🇺🇸
Memorial Sloan Kettering, New York, New York, United States

A Pilot Study of Using Video Images in Advance Care Planning in Malignant Glioma Patients

Not Applicable

Completed

Conditions: Advanced Brain Cancer

Interventions: Behavioral: Video intervention

First Posted Date: 2009-09-02

Last Posted Date: 2012-05-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT00970788

Locations: 🇺🇸
MGH, Boston, Massachusetts, United States

Statin Therapy to Improve Atherosclerosis in HIV Patients

Not Applicable

Completed

Conditions: Cardiovascular Disease
HIV
Atherosclerosis
Inflammation
Statins, HMG-CoA
HIV Infections

Interventions: Drug: Placebo
Drug: atorvastatin

First Posted Date: 2009-08-25

Last Posted Date: 2017-12-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 40

Registration Number: NCT00965185

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Once Weekly D-cycloserine for Schizophrenia

Phase 4

Withdrawn

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: D-cycloserine

First Posted Date: 2009-08-24

Last Posted Date: 2013-11-20

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00964041

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: D-cycloserine
Behavioral: Cognitive Remediation

First Posted Date: 2009-08-24

Last Posted Date: 2018-02-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 54

Registration Number: NCT00963924

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy